<DOC>
	<DOCNO>NCT02745639</DOCNO>
	<brief_summary>This prospective phase II study patient locally advanced rectal cancer local recurrence , evaluate pathological response resectability neoadjuvant treatment base use combine treatment VMAT-SIB two drug chemotherapy ( XELOX ) .</brief_summary>
	<brief_title>Preoperative Chemoradiation With VMAT-SIB Rectal Cancer</brief_title>
	<detailed_description>This prospective phase II study patient LARC local recurrence , evaluate pathological response resectability neoadjuvant treatment base use combine treatment VMAT-SIB two drug chemotherapy ( XELOX ) . The primary aim asses pathological response rate . Key secondary aim acute toxicity . Secondary aim local control , disease-free survival ( DFS ) overall survival ( OS ) . The follow-up period subject start end combine treatment conclude period maximum 60 month death .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>) histologically proven rectal adenocarcinoma ( cT34N02 cT2N12 locally recurrent ) begin within 12 cm anal verge ; ii ) age â‰¥ 18 year ; iii ) Eastern Eastern Cooperative Oncology Group ( ECOG ) performance status 02. ) history chemotherapy and/or pelvic radiotherapy ; ii ) previous treatment immunotherapy ; iii ) metastatic patient ; iv ) presence active intestinal inflammation uncontrolled pelvic inflammation ; v ) pregnant and/or breastfeeding patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>rectal cancer</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>VMAT</keyword>
	<keyword>toxicity</keyword>
</DOC>